Authors
Niall C Tebbutt, Kate Wilson, Val J Gebski, Michelle M Cummins, Diana Zannino, Guy A Van Hazel, Bridget Robinson, Adam Broad, Vinod Ganju, Stephen P Ackland, Garry Forgeson, David Cunningham, Mark P Saunders, Martin R Stockler, YuJo Chua, John R Zalcberg, R John Simes, Timothy J Price
Publication date
2010/7/1
Journal
Journal of clinical oncology
Volume
28
Issue
19
Pages
3191-3198
Publisher
American Society of Clinical Oncology
Description
Purpose
To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial.
Patients and Methods
Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab, and mitomycin (CBM). We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL).
Results
Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM (capecitabine v CB: hazard ratio [HR], 0.63; 95% CI, 0.50 to 0.79; P < .001 …
Total citations
Scholar articles
NC Tebbutt, K Wilson, VJ Gebski, MM Cummins… - Journal of clinical oncology, 2010